Your browser doesn't support javascript.
loading
Timeliness of Point-of-Care Viral Load Results Improves Human Immunodeficiency Virus Monitoring in Nigeria.
Chaplin, Beth; Agbaji, Oche; Reyes Nieva, Harry; Olatunde, Bola; Chang, Charlotte; Mitruka, Kiren; Sule, Halima; Dajel, Titus; Zee, Aaron; Ahmed, Mukhtar L; Ahmed, Isah; Okonkwo, Prosper; Rawizza, Holly; Kanki, Phyllis.
Afiliação
  • Chaplin B; Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Agbaji O; Department of Medicine, Jos University Teaching Hospital, Jos, Nigeria.
  • Reyes Nieva H; Department of Biomedical Informatics, Columbia University, New York, New York, USA.
  • Olatunde B; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Chang C; Department of Medicine, Jos University Teaching Hospital, Jos, Nigeria.
  • Mitruka K; Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Sule H; Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Dajel T; Department of Medicine, Jos University Teaching Hospital, Jos, Nigeria.
  • Zee A; Department of Medicine, Jos University Teaching Hospital, Jos, Nigeria.
  • Ahmed ML; Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Ahmed I; Centers for Disease Control and Prevention, Abuja, Nigeria.
  • Okonkwo P; APIN Public Health Initiatives, Abuja, Nigeria.
  • Rawizza H; APIN Public Health Initiatives, Abuja, Nigeria.
  • Kanki P; Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Clin Infect Dis ; 76(3): e671-e680, 2023 02 08.
Article em En | MEDLINE | ID: mdl-35872644
ABSTRACT

BACKGROUND:

Human immunodeficiency virus (HIV) viral load (VL) monitoring is critical for antiretroviral therapy (ART) management. Point-of-care (POC) VL testing has been reported to be feasible and preferred over standard-of-care (SOC) testing in many low- and middle-income country settings where rapid results could improve patient outcomes.

METHODS:

The timeliness of receipt of VL results was evaluated in an open-label, randomized, controlled trial among patients newly initiating ART. Clinical outcomes with POC VL monitoring using Cepheid Xpert vs SOC VL at Jos University Teaching Hospital and Comprehensive Health Centre Zamko in Nigeria were assessed. We determined time between specimen collection and recording of VL in patient charts, receipt of results, and ART switch for those who met virologic failure criteria.

RESULTS:

Between April 2018 and October 2019, we screened 696 ART-naive individuals; 273 were randomized to POC and 268 to SOC HIV-1 VL testing. Participants in the POC arm received VL results significantly faster than those in the SOC arm (0.1 median days, interquartile range [IQR], 0.1-0.2 vs 143.1 days, IQR, 56.0-177.1, respectively; P < .0001). Participants in the POC arm with confirmed virologic failure vs those in the SOC arm were switched more rapidly to a second-line regimen (0 median days, IQR, 0-28 vs 66 days, IQR, 63-123, respectively; P = .03).

CONCLUSIONS:

POC VL testing resulted in significant improvement in the timeliness of VL result receipt by patients and use for effective HIV clinical management. In patients experiencing VL failure, POC monitoring enabled prompt switching to second-line ART regimens. CLINICAL TRIALS REGISTRATION NCT03533868.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Fármacos Anti-HIV Tipo de estudo: Clinical_trials Limite: Humans País/Região como assunto: Africa Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Fármacos Anti-HIV Tipo de estudo: Clinical_trials Limite: Humans País/Região como assunto: Africa Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos